Global Type 1 Diabetes (T1D) Market Growth 2023-2029

Global Type 1 Diabetes (T1D) Market Growth 2023-2029

Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.

LPI (LP Information)' newest research report, the “Type 1 Diabetes (T1D) Industry Forecast” looks at past sales and reviews total world Type 1 Diabetes (T1D) sales in 2022, providing a comprehensive analysis by region and market sector of projected Type 1 Diabetes (T1D) sales for 2023 through 2029. With Type 1 Diabetes (T1D) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type 1 Diabetes (T1D) industry.

This Insight Report provides a comprehensive analysis of the global Type 1 Diabetes (T1D) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Type 1 Diabetes (T1D) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Type 1 Diabetes (T1D) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type 1 Diabetes (T1D) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type 1 Diabetes (T1D).

The global Type 1 Diabetes (T1D) market size is projected to grow from US$ 1859.8 million in 2022 to US$ 2577.5 million in 2029; it is expected to grow at a CAGR of 2577.5 from 2023 to 2029.

Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Type 1 Diabetes (T1D) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs

Segmentation by application
Children
Adults

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi

Key Questions Addressed in this Report

What is the 10-year outlook for the global Type 1 Diabetes (T1D) market?

What factors are driving Type 1 Diabetes (T1D) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Type 1 Diabetes (T1D) market opportunities vary by end market size?

How does Type 1 Diabetes (T1D) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.